Clinical Trial

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone. Researchers want to learn if a trial medicine called bomedemstat, also called MK-3543, can treat PV. In this study, researchers will compare bomedemstat to 2 usual treatments for PV. The goal of this study is to learn if more participants who take bomedemstat reach healthy blood cell counts and avoid major health problems from PV, compared to those who receive a usual treatment.
Trial Details
NCT Number NCT07722611
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Polycythemia Vera
Enrollment 380 participants
Start Date 2026-09-21
Primary Completion 2032-06-25 (estimated)
Study Completion 2032-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23